The Chicago-based Tempus spinout called the financing round a major milestone as it expands its AI-enabled platform.

Tempus AI TEM, an innovator in artificial intelligence-based healthcare solutions, has been attracting investors' interest ...

FDA Commissioner Marty Makary said Thursday that his agency is preparing to release a new regulatory framework within the ...

CEO Önal said Türk Telekom had a ‘spectacular’ start to the year, primarily driven by the maintained strength in fixed ...

Tezepelumab demonstrated rapid and sustained clinical improvements in nasal polyp burden and symptom control, with effects ...

The treatment, branded as Emrelis, belongs to a class of drugs known as antibody-drug conjugates, which act as ...

Controlling the entire cell therapy production process—from material receipt to product release—is “essential,” according to AstraZeneca, which says its new $300 million manufacturing facility will be ...

A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...

Food allergy in children with atopic dermatitis is associated with an increased risk for asthma, allergic rhinitis, and ...

In 2024 alone, Singapore secured S$13.5 billion in fixed asset investment commitments, with the biomedical sector ...

A new treatment approach significantly improves survival rates for patients with aggressive, inherited breast cancers, according to researchers. In a trial where cancers were treated with chemotherapy ...

A federal appellate court has handed down the first appellate-level decision addressing the merits of drug manufacturers’ ...